FDA nano-teams with academia
This article was originally published in The Tan Sheet
FDA collaborates with the Alliance for NanoHealth to hasten development of novel medical products using nanotechnology. The FDA/ANH Nanotechnology Initiative aims to expand understanding of how nanoparticles affect biologic systems and develop processes to potentially mitigate nano-related risks, all of which will be placed in the public domain. FDA March 10 said the collaboration is part of its Critical Path initiative for biomarker validation, better clinical trial design and new manufacturing methods (1"The Tan Sheet" Oct. 3, 2005, p. 7)
You may also be interested in...
The appointment of National Cancer Institute Director Andrew von Eschenbach to FDA acting commissioner is likely to revitalize the agency's stalled Critical Path initiative
The appointment of Belén Garijo as CEO of the German major from May next year is a small but significant step on the road to addressing gender inequality at the very top level of management in the world of big pharma.
The FDA has published fresh guidance taking a tougher stance on sponsor reasons for needing more time to respond to complete response letters.